Abstract:Abstract Background: Immune checkpoint inhibitors (ICI’s) are now indicated in the treatment of several solid tumors and have improved the prognosis of patients with advanced malignancy. The expanded use of ICI’s has led to the rise of otherwise rare autoimmune sequelae. The overall incidence of ICI-induced autoimmune hypophysitis has increased to approximately 10%, but is only estimated to be 0.4% with PD-1 inhibitors specifically (1). Isolated ACTH deficiency from immune checkpoint inhibitors is rare, and very few cases secondary to the PD-1 inhibitor pembrolizumab have thus far been reported. Clinical Case: A 75-year old woman with history of Stage IV lung adenocarcinoma presented to oncology clinic in July 2019 with progressive weakness, weight loss, and confusion for several weeks. She was found to be hypotensive and dehydrated in the clinic and subsequently was admitted to the hospital. A comprehensive infectious work-up was non-contributory. History revealed that after treatment failure with carboplatin, she was treated with pembrolizumab from January 2017 to June 2019 with excellent response. Laboratory evaluation on admission demonstrated an undetectable AM cortisol level of < 1 ug/dL (n 5-25 ug/dL) with concomitant ACTH < 5pg/mL (Roche cobas, n 7.2-63 pg/mL), consistent with central adrenal insufficiency. Testing of the remainder of the pituitary axis, including TSH (0.83uU/mL, n 0.4-4.6 uU/mL), FSH (34.7 mIU/mL, n <150mIU/mL), LH (12.6mIU/mL, n <60 mIU/mL), and IGF-1 (33ng/mL, n 34-245ng/mL), all returned within normal limits. Further chart review verified that she had not been exposed to any form of glucocorticoids within the past 6 months. MRI brain with contrast demonstrated no obvious pituitary disease. The patient was started on 5mg of prednisone daily, with significant improvement in mental status, appetite, and blood pressure. She was discharged home on maintenance prednisone for adrenal insufficiency due to presumed isolated corticotroph destruction. Conclusions: Isolated ACTH deficiency is a very rare but potential consequence of pembrolizumab use. It can be especially difficult to diagnose in patients on chemotherapy who are at higher risk for dehydration and failure to thrive. Duration of pembrolizumab therapy should not preclude the diagnosis of isolated ACTH deficiency, as it can occur even as late as 2.5 years into therapy. Reference: (1) Chang, L., Barroso-Sousa, R., Tolaney S., Hodi F.S., Kaiser, U.B., Min, L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints, Endocr Rev. 2019;40;17–65.

Immunotherapy-Induced Hypophysitis Following Treatment with Tislelizumab in an Elderly Patient with Bladder Cancer and Prostate Cancer: A Case Report.

Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report

Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event

Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature

Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD ‐1 inhibitor (sintilimab) in small cell lung cancer: A case report

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis

Pituitary-adrenal Axis Dysfunction Induced by Tislelizumab Immunotherapy for Non-Small Cell Lung Cancer: a Case Series and Literature Review

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review

Thyroid Dysfunction Induced by Immune Checkpoint Inhibitors and Tumor Progression During Neoadjuvant Therapy of Non‑small Cell Lung Cancer: A Case Report and Literature Review.

Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS

SAT-242 Isolated Adrenocorticotropic Hormone Deficiency Secondary to the PD-1 Inhibitor Pembrolizumab

Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report

Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment

The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis

The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database

Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.

Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review

Immune Checkpoint Inhibitor-Associated New-Onset Primary Adrenal Insufficiency: a Retrospective Analysis Using the FAERS.

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature